Talk evidence covid-19 update - remdesivir redux, the overwhelming volume of research - a podcast by BMJ Group

That remdesivir study has finally been published - what does it say and is it as independant as claimed. Also, as the world's focus turned to covid, so have researchers - and they've produced over 15000 papers. How can we sift through the flood of research and know what's any good?

(2.30) Helen Macdonald talks to Elizabeth Loder about the volume of research we're seeing, and why journals and peer reviewers are struggling to check it all.(8.15) The study on remdesivir has been published - the trial was stopped early, and the primary outcome switched - we talk about how that increases uncertainty over the results, and could actually delay the treatment.

(26.50) We hear from a couple fo readers who wanted to correct us about averages, means, medians.Reading list:
The US NIH AID study on remdesivir, published 22nd May in the New England Journal of MedicineResearch - preliminary report https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
NEJM - looking at the dose duration https://www.nejm.org/doi/full/10.1056/NEJMoa2015301

Editorial - an important first step https://www.nejm.org/doi/full/10.1056/NEJMe2018715

Further episodes of The BMJ Podcast

Further podcasts by BMJ Group

Website of BMJ Group